Edwards Lifesciences plans to submit additional data for the Sapien 3 Ultra valve before it files for CE mark, causing a slight delay in the product getting to the market.
In a deal set to boost its urology offerings, Boston Scientific said it will acquire NxThera for about $406 million.
Colibri has treated the first two patients in a feasibility study and cites Edwards Lifesciences as its main competition in the TAVR market.
Johnson & Johnson continues its exodus from the diabetes market and has received a $2.1B offer from Platinum Equity to acquire LifeScan.
Corindus Vascular tops revenue expectations for the fourth quarter of 2017 and gears up for tele-stenting trial with Mayo Clinic.
Qiagen, known for its oncology offerings, is set to develop assays for the non-invasive prenatal testing market through a $40 million collaboration with Natera.
FDA gave the company the green light to end a trial of its LAP-BAND System early, saving the company more than $5 million.
Medtronic continued to strengthen its TAVR story with 5-year-data recently presented at ACC18. The company is battling it out with Edwards in the U.S. market, while Boston Scientific seeks to find footing after delaying commercialization of the Lotus Edge valve.
Laborie Medical Technologies is poised to get a leg up in the urology market by acquiring Cogentix Medical for about $239 million.
Strong results from the MOMENTUM 3 clinical trial could help Abbott take a significant part of the destination therapy portion of the LVAD market from Medtronic.
Cleveland Clinic Innovation Executive Director sees 3D Printing more suited for custom implants as opposed to mass producing products in healthcare.